IVA337 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scleroderma, Diffuse
Conditions
Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis
Trial Timeline
Oct 29, 2015 → Oct 12, 2018
NCT ID
NCT02503644About IVA337 + Placebo
IVA337 + Placebo is a phase 2 stage product being developed by Inventiva for Scleroderma, Diffuse. The current trial status is completed. This product is registered under clinical trial identifier NCT02503644. Target conditions include Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04849728 | Phase 3 | Recruiting |
| NCT02503644 | Phase 2 | Completed |
Competing Products
15 competing products in Scleroderma, Diffuse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cuprimine (penicillamine) | Merck | Pre-clinical | 23 |
| rapcabtagene autoleucel + rituximab | Novartis | Phase 2 | 52 |
| STI571 | Novartis | Phase 2 | 52 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Mycophenolate mofetil | Roche | Pre-clinical | 23 |
| Mycophenolate mofetil + Cyclophosphamide + Placebo | Roche | Phase 2 | 52 |
| Fludarabine + Cyclophosphamide + Thymoglobulin | Amgen | Phase 1 | 32 |
| BMS-986020 | Bristol Myers Squibb | Phase 2 | 51 |
| dasatinib | Bristol Myers Squibb | Phase 1/2 | 40 |
| Abatacept + Placebo | Bristol Myers Squibb | Phase 1/2 | 40 |
| AVID200 | Bristol Myers Squibb | Phase 1 | 32 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Riociguat + Placebo | Bayer | Phase 2 | 49 |
| Riociguat (Adempas, BAY63-2521) + Placebo | Bayer | Phase 2 | 49 |